Sensus Healthcare (NASDAQ:SRTS) Shares Cross Below 50-Day Moving Average – Here’s Why

Sensus Healthcare, Inc. (NASDAQ:SRTS)’s stock price passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.97 and traded as low as $2.86. Sensus Healthcare shares last traded at $3.23, with a volume of 103,027 shares changing hands.

Analyst Upgrades and Downgrades

SRTS has been the subject of a number of analyst reports. Alliance Global Partners restated a “buy” rating on shares of Sensus Healthcare in a research report on Monday. Lake Street Capital lowered their target price on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a research report on Friday, May 8th. Finally, Weiss Ratings lowered Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $5.83.

Sensus Healthcare Price Performance

The company has a 50-day simple moving average of $2.97 and a 200-day simple moving average of $3.58. The stock has a market cap of $53.17 million, a PE ratio of -3.44 and a beta of 1.10.

Sensus Healthcare (NASDAQ:SRTS) last issued its earnings results on Thursday, August 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The company had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.60 million.

Institutional Trading of Sensus Healthcare

A number of institutional investors have recently added to or reduced their stakes in the stock. EP Wealth Advisors LLC acquired a new position in Sensus Healthcare during the second quarter worth about $49,000. XTX Topco Ltd acquired a new stake in shares of Sensus Healthcare during the 4th quarter valued at approximately $77,000. Jane Street Group LLC purchased a new stake in shares of Sensus Healthcare during the 4th quarter worth approximately $79,000. Ingalls & Snyder LLC purchased a new stake in shares of Sensus Healthcare during the 4th quarter worth approximately $219,000. Finally, State Street Corp grew its holdings in shares of Sensus Healthcare by 5.2% in the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after acquiring an additional 3,400 shares during the period. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.